Compositions targeting prostate-specific membrane antigen and methods for making and using the same
US12428494B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2025 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Feb 25, 2045 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure describes antigen-binding molecules with binding specificity to cluster of differentiation 3 T cell receptor (CD3), antigen-binding molecules with binding specificity to prostate-specific membrane antigen (PSMA), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.